Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

Stereoselective Metabolism of Ifosfamide by Human P-450s 3A4 and 2B6. Favorable Metabolic Properties of R-Enantiomer

Partha Roy, Olga Tretyakov, Joel Wright and David J. Waxman
Drug Metabolism and Disposition November 1999, 27 (11) 1309-1318;
Partha Roy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Tretyakov
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Wright
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David J. Waxman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The anticancer prodrug ifosfamide (IFA) contains a chiral phosphorous atom and is administered clinically as a racemic mixture ofR and S enantiomers. Animal model studies and clinical data indicate enantioselective differences in cytochrome P-450 (CYP) metabolism, pharmacokinetics, and therapeutic efficacy between the two enantiomers; however, the metabolism of individual IFA enantiomers has not been fully characterized. The role of CYP enzymes in the stereoselective metabolism of R-IFA andS-IFA was investigated by monitoring the formation of both 4-hydroxy (activated) and N-dechloroethyl (DCl) (inactive, neurotoxic) metabolites. In the 4-hydroxylation reaction, cDNA-expressed CYPs 3A4 and 3A5 preferentially metabolizedR-IFA, whereas CYP2B6 was more active towardS-IFA. Enantioselective IFA 4-hydroxylation (R > S) was observed with six of eight human liver samples. In the N-dechloroethylation reaction, CYPs 3A4 and 2B6 both catalyzed a significantly higher intrinsic metabolic clearance (Vmax/Km) ofS-IFA compared with R-IFA. Striking P-450 form specificity in the formation of individual DCl metabolites was evident. CYPs 3A4 and 3A5 preferentially produced (R)N2-DCl-IFA and (R)N3-DCl-IFA (derived from R-IFA and S-IFA, respectively), whereas CYP2B6 correspondingly formed (S)N3-DCl-IFA and (S)N2-DCl-IFA. In human liver microsomes, the CYP3A-specific inhibitor troleandomycin suppressed (R)N2- and (R)N3-DCl-IFA formation by ≥80%, whereas (S)N2- and (S)N3-DCl-IFA formation were selectively inhibited (≥85%) by a CYP2B6-specific monoclonal antibody. The overall extent of IFAN-dechloroethylation varied with the CYP3A4 and CYP2B6 content of each liver, but was significantly lower forR-IFA (32 ± 13%) than for S-IFA (62 ± 17%, n = 8; p < .001) in all livers examined. R-IFA thus has more favorable liver metabolic properties than S-IFA with respect to less extensive N-dechloroethylation and more rapid 4-hydroxylation, indicating that R-IFA may have a distinct clinical advantage over racemic IFA.

Footnotes

  • Send reprint requests to: Dr. David J. Waxman, Department of Biology, Boston University, 5 Cummington St., Boston, MA. E-mail: djw{at}bio.bu.edu

  • This work was supported in part by National Institutes of Health Grant CA49248 (to D.J.W.).

  • Abbreviations used are::
    CYP
    cytochrome P-450
    IFA
    ifosfamide
    rac-IFA
    racemic IFA
    CPA
    cyclophosphamide
    DCl
    dechloroethyl
    R2-DCl-IFA and S2-DCl-IFA
    N2-dechloroethylated metabolites of R-IFA andS-IFA, respectively
    S3-DCl-IFA and R3-DCl-IFA
    N3-dechloroethylated metabolites ofR-IFA and S-IFA, respectively
    HLS
    human liver microsomal sample
    OR
    NADPH P-450 oxidoreductase
    mAb-2B6
    monoclonal antibody to CYP2B6
    TAO
    troleandomycin
    7-EFC
    7-ethoxy-4-trifluoromethyl coumarin
    • Received May 4, 1999.
    • Accepted August 2, 1999.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 27 (11)
Drug Metabolism and Disposition
Vol. 27, Issue 11
1 Nov 1999
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Stereoselective Metabolism of Ifosfamide by Human P-450s 3A4 and 2B6. Favorable Metabolic Properties of R-Enantiomer
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Stereoselective Metabolism of Ifosfamide by Human P-450s 3A4 and 2B6. Favorable Metabolic Properties of R-Enantiomer

Partha Roy, Olga Tretyakov, Joel Wright and David J. Waxman
Drug Metabolism and Disposition November 1, 1999, 27 (11) 1309-1318;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Stereoselective Metabolism of Ifosfamide by Human P-450s 3A4 and 2B6. Favorable Metabolic Properties of R-Enantiomer

Partha Roy, Olga Tretyakov, Joel Wright and David J. Waxman
Drug Metabolism and Disposition November 1, 1999, 27 (11) 1309-1318;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Identification of payload-containing catabolites of ADCs
  • PK Interactions of Licorice with Cytochrome P450s
  • Biotransformation of Trastuzumab and Pertuzumab
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics